The Food and Drug Administration has created a formal regulatory category for a device most parents have never heard of: a system that sits with a newborn incubator and cancels out the noise reaching the baby inside.
The agency published a final order in the Federal Register classifying the active noise attenuation system for infant incubators into Class II with special controls. The order took effect on publication and adds a new section, 21 CFR 880.5405, to the code governing general hospital devices.
The practical consequence is procedural rather than clinical. No new product reached the market this week, and no hospital is required to buy anything. What changed is the pathway. Future manufacturers of similar systems can now use the less burdensome premarket notification route instead of applying for full premarket approval, and every such device must meet a defined set of testing and labeling requirements.
What the Device Is and Why NICUs Want One
FDA defines the device type as a system that captures environmental noise and outputs noise-canceling acoustic sound waves to reduce noise inside infant incubators in a health care setting. It is the same physical principle as noise-canceling headphones, applied to a plastic box in a busy intensive care unit rather than to a pair of ears.
The problem it addresses is well documented. The American Academy of Pediatrics recommends that sound levels in neonatal intensive care units stay below 45 decibels. Published measurements have repeatedly found real units running above that threshold for much of the day, with alarms, ventilators, infusion pumps, air-handling systems, and staff conversation all contributing. An incubator wall provides some barrier, but it also reflects and re-radiates sound, and some studies have found the incubator itself to be a noise source.
Sustained noise exposure has been associated in the research literature with disrupted sleep and effects on weight gain in preterm infants. Those associations come largely from observational work, and they should be read as associations rather than proof that quieting an incubator produces better long-term outcomes. That question has not been settled by a clinical trial.
How the Classification Happened
The regulatory history runs longer than the publication date suggests. Invictus Medical, Inc., a San Antonio company, submitted a De Novo classification request for its Neoasis device on July 25, 2022. FDA reviewed it and issued an order classifying the device into Class II on June 16, 2023. This week's Federal Register document is the step that writes that decision into the Code of Federal Regulations.
The De Novo pathway exists because of a quirk in device law. Any device not in commercial distribution before May 28, 1976, is automatically placed in Class III by operation of law, regardless of how risky it actually is. Class III normally requires full premarket approval, which is expensive and slow. De Novo classification lets FDA move a genuinely novel but lower-risk device down to Class I or Class II, and once that happens, the device can serve as a predicate for later products.
FDA stated in the order that the action would enhance patient access to beneficial innovation "in part by reducing regulatory burdens." Active noise attenuation systems still require premarket notification under section 510(k). The agency has not exempted the category from that requirement.
The Safety Requirements Manufacturers Must Now Meet
The order identifies three risks to health and the measures required to address each.
The first and most significant is hearing loss, which FDA links to two failure modes: a device that outputs too much sound of its own, and a device that simply does not attenuate noise effectively. A system marketed as protective that quietly fails to work is a genuine hazard, because staff may relax other noise-control practices while believing the baby is protected.
To address that, manufacturers must perform non-clinical performance testing under anticipated use conditions. That testing must verify and validate critical acoustic parameters including the device's maximum output, and must validate attenuation performance across compatible incubator models and dimensions, across different infant positions and orientations inside the incubator, and with relevant noise sources and room configurations. Software validation, verification, and hazard analysis are required, as are electrical safety and electromagnetic compatibility testing for electrical components.
The second identified risk is infection, addressed through labeling. The third is adverse tissue reaction, addressed by requiring that any patient-contacting or user-contacting components be demonstrated biocompatible.
Labeling must include instructions for infant placement and the expected attenuation performance, warnings about exposure to the device's potential maximum output, cleaning and disinfection methods, and identification of which specific incubators the device is intended to be used with. That last requirement matters clinically. A system validated on one incubator model cannot be assumed to perform the same way on another.
What Parents of a NICU Baby Should Take from This
If your infant is currently in a neonatal intensive care unit in Houston, Chicago, Phoenix or anywhere else, this order does not change your baby's care today. It does not mean a device is available at your hospital, and it is not a recommendation that any hospital acquire one.
Parents who want to ask a useful question can ask the unit's charge nurse or neonatologist what the unit does to manage sound levels. Many NICUs already use quiet hours, alarm threshold management, single-family rooms and staff training. Those approaches have evidence behind them and cost nothing to ask about.
What remains genuinely unknown is whether active noise cancellation improves the outcomes parents actually care about, including neurodevelopment, hearing and length of stay. FDA's classification is a judgment that the device type can be made reasonably safe and effective for its stated purpose of reducing noise. It is not a finding that quieter incubators produce healthier babies. Demonstrating that would require clinical trials that have not yet been done at scale.
Manufacturers may now submit 510(k) notifications for substantially equivalent systems, which could bring additional products forward over the coming years. MedicalDaily will monitor FDA device databases for new clearances in this category and for any clinical outcome data as it is published.
Related MedicalDaily.com Coverage
Frequently Asked Questions
What exactly did FDA approve? FDA did not approve a specific product. It created a regulatory category, classifying active noise attenuation systems for infant incubators as Class II devices with special controls and codifying that at 21 CFR 880.5405.
Does this mean my hospital will get one? No. The classification sets requirements for manufacturers. It does not require, recommend or fund purchase by any hospital, and it does not indicate that a device is available at any particular facility.
How loud are NICUs actually? The American Academy of Pediatrics recommends staying below 45 decibels. Published measurements have repeatedly found real units exceeding that level for a substantial share of the day because of alarms, ventilators, pumps and conversation.
Is there proof that quieter incubators improve outcomes? Not yet at the level of clinical trial evidence. Research has associated noise exposure with disrupted sleep and effects on weight gain, but association is not proof, and outcome benefits from active noise cancellation remain unestablished.
What safety testing is now required? Acoustic testing including maximum device output, attenuation validation across incubator models and infant positions, software validation and hazard analysis, electrical safety and electromagnetic compatibility testing, and biocompatibility of contacting components.
Why did classification take until 2026 for a 2023 decision? FDA issued the classification order to the requesting company on June 16, 2023. The July 2026 Federal Register document is the separate administrative step that writes the decision into the Code of Federal Regulations.
What can parents in a NICU do now? Ask the charge nurse or neonatologist how the unit manages sound levels. Established practices such as quiet hours, alarm threshold management and single-family rooms are already in wide use and are reasonable to ask about.
